Aromatase inhibitors in the treatment of postmenopausal breast cancerBAJETTA, E; ZILEMBO, N; BICHISAO, E et al.Drugs & aging. 1999, Vol 15, Num 4, pp 271-283, issn 1170-229XArticle

Steroidal aromatase inhibitors in elderly patientsBAJETTA, E; ZILEMBO, N; BICHISAO, E et al.Critical reviews in oncology/hematology. 2000, Vol 33, Num 2, pp 137-142, issn 1040-8428Article

Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trialPROCOPIO, G; VERZONI, E; BRACARDA, S et al.British journal of cancer. 2011, Vol 104, Num 8, pp 1256-1261, issn 0007-0920, 6 p.Article

Combination goserelin and tamoxifen therapy in premenopausal advanced breast cancer : a multicentre study by the ITMO groupBUZZONI, R; BIGANZOLI, L; AITINI, E et al.British journal of cancer. 1995, Vol 71, Num 5, pp 1111-1114, issn 0007-0920Article

Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancerBAJETTA, E; ZILEMBO, N; NELLI, P et al.British journal of cancer. 1994, Vol 70, Num 1, pp 145-150, issn 0007-0920Article

Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology studyBIDOLI, P; ZILEMBO, N; FORMISANO, B et al.Annals of oncology. 2007, Vol 18, Num 3, pp 461-467, issn 0923-7534, 7 p.Article

Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patientsFERRARI, L; MARTINETTI, A; SEREGNI, E et al.Journal of steroid biochemistry and molecular biology. 2002, Vol 80, Num 4-5, pp 411-418, issn 0960-0760Article

Salvage treatment after rinterferon α-2a in advanced neuroendocrine tumorsZILEMBO, N; BUZZONI, R; FOSSER, V et al.Acta oncologica (Stockholm). 1993, Vol 32, Num 2, pp 245-250, issn 0284-186XConference Paper

Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients : Results of randomised phase II studyBAJETTA, E; DI BARTOLOMEO, M; JACOBELLI, S et al.British journal of cancer. 2007, Vol 96, Num 3, pp 439-444, issn 0007-0920, 6 p.Article

Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitorsBAJETTA, E; ZILEMBO, N; BICHISAO, E et al.Annals of oncology. 2000, Vol 11, Num 8, pp 1017-1022, issn 0923-7534Article

Efficacy and tolerability of 4-hydroxyandrostenedione (4-OHA) as first-line treatment in postmenopausal patients with breast cancer after adjuvent therapyBAJETTA, E; ZILEMBO, N; BUZZONI, R et al.Cancer treatment reviews. 1993, Vol 19, pp 31-36, issn 0305-7372, SUPBConference Paper

Treatment of carcinoid syndrome with recombinant interferon alpha-2aDI BARTOLOMEO, M; BAJETTA, E; EPIFANI, C et al.Acta oncologica (Stockholm). 1993, Vol 32, Num 2, pp 235-238, issn 0284-186XConference Paper

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer : Results of a phase III randomized double-blind trialKAUFMANN, M; BAJETTA, E; FOWST, C et al.Journal of clinical oncology. 2000, Vol 18, Num 7, pp 1399-1411, issn 0732-183XArticle

Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumorsBAJETTA, E; FERRARI, L; MARTINETTI, A et al.Cancer. 1999, Vol 86, Num 5, pp 858-865, issn 0008-543XConference Paper

Hormone therapy in advanced breast carcinoma: present and future trendsBAJETTA, E; ZILEMBO, N; DI LEO, A et al.Cancer treatment reviews. 1994, Vol 20, Num 3, pp 241-258, issn 0305-7372Article

Effect of two 4-hydroxyandrostenedione doses on serum insulin-like growth factor I levels in advanced breast cancerFERRARI, L; ZILEMBO, N; BAJETTA, E et al.Breast cancer research and treatment. 1994, Vol 30, Num 2, pp 127-132, issn 0167-6806Article

Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a : a study by the Italian trials in medical oncology groupBAJETTA, E; ZILEMBO, N; PINOTTI, G et al.Cancer. 1993, Vol 72, Num 10, pp 3099-3105, issn 0008-543XArticle

Cell kinetics and tumor-associated antigen expression in human mammary carcinomasCONTEGIACOMO, A; MARIANI COSTANTINI, R; BIANCO, A. R et al.The International journal of biological markers. 1991, Vol 6, Num 3, pp 159-166, issn 0393-6155Article

Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trialPROCOPIO, G; VERZONI, E; BRACARDA, S et al.Annals of oncology. 2013, Vol 24, Num 12, pp 2967-2971, issn 0923-7534, 5 p.Article

Gemcitabine plus vinorelbine as first-line chemotherapy in advanced nonsmall cell lung carcinoma a Phase II trialBAJETTA, E; STANI, S. C; DE CANDIS, D et al.Cancer. 2000, Vol 89, Num 4, pp 763-768, issn 0008-543XConference Paper

Effects of short-term pre-operative tamoxifen on steroid receptor and Ki-67 expression in primary breast cancer : an immunocytochemical studyBAJETTA, E; CELIO, L; DE CANDIS, D et al.International journal of oncology. 1998, Vol 12, Num 4, pp 853-858, issn 1019-6439Article

A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: Endocrine and clinical resultsBAJETTA, E; ZILEMBO, N; D'APRILE, M et al.Annals of oncology. 1997, Vol 8, Num 7, pp 649-654, issn 0923-7534Article

Effects of aromatase complex selective inhibition on insulin-like growth factor 1 and insulin-like growth factor binding protein 3 circulating levels in breast cancerFERRARI, L; BAJETTA, E; CELIO, L et al.International journal of oncology. 1997, Vol 11, Num 1, pp 163-167, issn 1019-6439Article

Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitorZILEMBO, N; NOBERASCO, C; MARIANI, L et al.British journal of cancer. 1995, Vol 72, Num 4, pp 1007-1012, issn 0007-0920Article

Formestane : an effective first-line endocrine treatment for advanced breast cancerZILEMBO, N; BAJETTA, E; NOBERASCO, C et al.Journal of cancer research and clinical oncology. 1995, Vol 121, Num 6, pp 378-382, issn 0171-5216Article